XTACY Therapeutics Provides Bi-Weekly MCTO Status Update
Vancouver, February, 13, 2024 – XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (the “Company”) is providing a bi-weekly default status update in accordance
Vancouver, February, 13, 2024 – XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (the “Company”) is providing a bi-weekly default status update in accordance
Vancouver, February 7th 2024 – XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (“Xtacy” or the “Company”) is pleased to announce an LOI with
Vancouver January 30, 2024 – XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (“Xtacy Therapeutics” or the “Company”) announces today a Management Cease